<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03665064</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00048323</org_study_id>
    <nct_id>NCT03665064</nct_id>
  </id_info>
  <brief_title>Long Term Outcome Study in Patients With Pituitary Disorders</brief_title>
  <official_title>Long Term Outcome Study in Patients With Pituitary Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the outcomes of patients with different pituitary disorders whether they are&#xD;
      managed medically, surgically or expectantly.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A chart audit of around 1500 patients seen in two specific clinics, the Medical Pituitary&#xD;
      Clinic and the combined Endocrine/Neurosurgical Pituitary Clinic at the University of Alberta&#xD;
      Hospital, will be performed to determine the effectiveness of various treatment strategies on&#xD;
      the long term outcome of specific pituitary disorders. The investigator's will collect&#xD;
      retrospective demographic (age, sex, ethnicity), clinical (mode of presentation, hormonal&#xD;
      parameters) and therapeutic outcome (surgical, medical, expectant and / or radiation&#xD;
      treatment; co-morbidities and complications) of patients seen in these two clinics between&#xD;
      January 2000 and December 2020.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2000</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival after pituitary surgery</measure>
    <time_frame>up to 17 years post surgery</time_frame>
    <description>Using clinical, biochemical and imaging studies of a cohort of surgically operated patients to identify prognostic factors of tumor recurrence</description>
  </primary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Pituitary Diseases</condition>
  <condition>Pituitary Neoplasms</condition>
  <eligibility>
    <study_pop>
      <textblock>
        tertiary referral center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with confirmed pituitary disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients who do not have confirmed pituitary disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2018</study_first_submitted>
  <study_first_submitted_qc>September 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2018</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pituitary tumor</keyword>
  <keyword>Acromegaly</keyword>
  <keyword>Cushing</keyword>
  <keyword>Prolactinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Neoplasms</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

